The article analyzes Eli Lilly's financial results for the third quarter: revenue grew 39% to $24,397 billion due to a 53% increase in sales volumes with a 15% price decrease, as well as the impact of these factors on the diabetes and obesity drug market, including prospects for retatrutide.
At first glance, Eli Lilly's third quarter looks like a celebration for shareholders: revenue increased 39% to $24,397 billion, and the company raised its 2026 forecast to $91–92 billion. But the real intrigue is hidden not in the pace of growth. According to the report dated October 29, physical sales volumes increased 53%, while realized prices decreased 15%. The pharmaceutical company is growing by expanding access to therapy, rather than by the ability to constantly raise the cost of treatment. This is exactly what is changing the rules for valuing the entire diabetes and obesity drug market.
The day before the report, Lilly published preliminary results from the phase 3 TRANSCEND-T2D-2 study, in which the experimental retatrutide was compared with Ozempic 2 mg. Clinical indicators were strong, but tolerability requires careful analysis, and the drug itself has not yet received approval for commercial use. As a result, the market is simultaneously evaluating two stories: the huge current revenue of Mounjaro and Zepbound and the possibility of the next generation of drugs to sustain growth after price competition intensifies.
Volume growth versus price reduction: who wins in the new model
A 53% increase in volumes with a 15% decrease in realized prices does not mean that the company “lost” 15% of revenue. Price, volume and assortment interact, and additional patients can compensate for the reduction in net income per dose. For chronic therapy, scale is particularly important: treatment can continue for a long time, and improved access through insurers and government programs expands the potential population. But high disease prevalence does not equal guaranteed solvent demand.
Lilly reported approximately $900 million in favorable factors in quarterly revenue. Among them were $410 million in milestone payments for Jardiance and adjustments to discount and rebate estimates. The company separately noted that additional milestone payments for Jardiance under the relevant agreement are no longer expected. Therefore, one cannot simply multiply quarterly revenue by four and consider the result a sustainable annual base. When normalizing the model, recurring drug sales must be separated from one-time contractual receipts and accounting adjustments.
In the US, sales increased 34% to $15.1 billion. Volume growth of 41% was accompanied by a 7% decrease in realized prices. Outside the US, revenue grew 47% to $9.3 billion, but volumes rose 76% while prices fell 29%. These are two different economies. In international markets, access to therapy often depends on inclusion in reimbursement lists, and coverage negotiations require price concessions. Lilly attributes part of the price reduction outside the US to the inclusion of Mounjaro in the Chinese reimbursement drug list.
For the investor, the question of marginal return is important: how profitable will the next million patients be? So far, the company demonstrates that scaling helps maintain margins. But if future agreements with insurers require ever deeper discounts, revenue may grow more slowly than the number of prescriptions. This does not necessarily mean commercial failure. A mature mass market is characterized by a combination of broad access and a lower price per unit; however, stock valuation must take this model shift into account.
Two brands, one molecule and revenue concentration
In the third quarter, Mounjaro brought in $10,723 billion, 65% more than a year earlier. Zepbound revenue reached $5,352 billion, up 49%. Together that is $16,075 billion, or about 65.9% of Lilly's total quarterly revenue. The share is calculated based on data published by the company. The two brands, linked to tirzepatide and different indications, effectively account for about two-thirds of the corporation's turnover. Concentration simultaneously provides scale and increases sensitivity to a single class of therapy.
The advantage of such a portfolio is obvious: manufacturing investments, clinical expertise and relationships with payers can support multiple markets. The disadvantage is that competition, regulatory changes or safety issues can affect a significant portion of revenue at once. Having buyers in dozens of countries does not eliminate molecular concentration. When assessing long-term value, geographic diversification must be distinguished from diversification by mechanism of action.
International Mounjaro sales grew 93% to $5.7 billion, while US sales reached approximately $5 billion, up 41%. This shows that geographic expansion has become an independent driver of the business. However, international expansion does not have to replicate the US margin structure. National healthcare systems evaluate not only efficacy but also the budgetary consequences of mass prescribing. A reduction in net price may be a condition for entering a much larger market.
Zepbound in the US brought in about $5.3 billion, 48% more than last year. For this franchise, insurance coverage rules, prescribing restrictions and the share of patients paying for treatment out of pocket are especially important. With high interest in therapy, lack of reimbursement can limit actual sales. Conversely, expanded access increases volume but often lowers the average realized price. Success depends on whether the company can improve overall profit in such a price-for-scale trade-off.
Clinical superiority and its commercial limitations
On October 28, Lilly reported results from the TRANSCEND-T2D-2 study involving 1,298 adults with type 2 diabetes. At 80 weeks, the mean HbA1c reduction was 2.2 percentage points in both retatrutide groups versus 1.8 points with Ozempic 2 mg. Weight loss reached 19.5% and 20.9% for the two retatrutide doses versus 9.4% for the comparator. These are the results of a specific study, not proof of universal superiority across all diseases and regimens.
The trial was randomized but open-label. The company reported achievement of the primary and key secondary endpoints, yet detailed results still need to be presented to the scientific community and published in a peer-reviewed journal. Until full data disclosure, it is important to maintain the distinction between declared final results, statistical criteria and long-term safety. Clinical efficacy is a necessary condition for success but does not replace regulatory decisions and real-world practice.
In the retatrutide 12 mg group, discontinuation due to adverse events was 7.9%, in the 9 mg group 4.8%, and with Ozempic 2 mg 2.7%. Lilly also reported gastrointestinal reactions including nausea, diarrhea and vomiting. Greater weight loss must be evaluated together with tolerability, titration schedule and treatment adherence. For mass chronic therapy, even a moderate increase in the proportion of patients discontinuing the course can substantially change the commercial outcome.
The comparison was made specifically with Ozempic 2 mg in a type 2 diabetes population. It cannot be automatically extrapolated to other doses, drugs, indications or patients with different baseline characteristics. Retatrutide remains an experimental drug. Therefore, it is premature to include it in a revenue model as an already approved product. An investor must separately assess the probability of approval, launch timing, future price, insurance coverage, manufacturing readiness and potential substitution of Lilly's existing drugs.
Why competition with Novo Nordisk is not limited to percentage weight loss
For makers of incretin drugs, the next stage of competition will be determined by the combination of efficacy, tolerability, convenience and affordability. Eli Lilly and Novo Nordisk differ in product portfolios, clinical programs and relationships with insurers. The result of a single head-to-head comparison can raise expectations for a new product, but does not conclude the competition. Physician recommendations, contraindications, long-term data and the ability to maintain stable supply can affect market share no less than individual clinical metrics.
If retatrutide receives approval, it could attract patients who need a more pronounced effect and retain part of Lilly's existing customer base. But a new product can cannibalize Mounjaro and Zepbound sales. For the shareholder, what matters is not the gross turnover of the newcomer but the additional profit of the group after accounting for patient switching, launch costs and pressure on prices of previous treatment regimens. Technological leadership and financial return from it do not always coincide in time.
Payers gain additional negotiating power as competing effective methods emerge. For patients this potentially means expanded choice, and for manufacturers a reduction in net price. An increase in the number of treated patients may be accompanied by a slowdown in revenue growth per patient. Hence the main risk to long-term forecasts: models based solely on obesity prevalence may overstate the economic size of the market if they ignore insurer budgets and real prescribing criteria.
At the same time, competition can expand the market by raising awareness, developing clinical guidelines and improving manufacturing processes. Therefore, the success of one manufacturer cannot be automatically considered equal to an equivalent monetary loss for another. The overall category can grow while its participants fight for share. But high stock valuations require not only category growth but confirmation of sustainable margins for each specific business.
84.4% margin: price pressure is still offset by scale
Lilly's adjusted gross profit rose 40% to $20.6 billion. The corresponding margin reached 84.4%, 0.8 percentage points higher than last year. The company attributes the improvement to a more favorable product mix and lower manufacturing costs, partially offset by lower prices. So far scale works: additional sales do not lead to a comparable destruction of gross profitability.
However, gross margin is not equal to free cash flow. Expanding the production of biopharmaceuticals requires plants, equipment, qualified personnel, quality control and inventory. Expenses for new capacities arise before the corresponding revenue. Lilly reported manufacturing investments, including projects in Texas and Virginia. Their future return depends on launch timing, validation and actual utilization. High demand today does not guarantee that every new plant will be equally profitable in a few years.
There is also a reverse risk. If capacity grows more slowly than patient demand, the company may face availability constraints and competitors gain an opportunity to strengthen their positions. If investments are calculated on an overly optimistic demand trajectory, excess capacity pressures return on capital. Therefore, it is more important to monitor actual output, cost of goods, supply stability and cash conversion than only the announced amount of capital expenditures.
Pharmaceutical manufacturing is particularly sensitive to quality. A line failure can lead not only to shipment delays but also to additional regulatory inspections. For a company with high revenue concentration in one class of drugs, such risks can have a substantial financial effect. Consequently, manufacturing discipline becomes part of competitive advantage on par with clinical efficacy.
Why earnings per share require more careful reading
Reported EPS for Lilly in the third quarter was $7.22, 16% higher than last year. Adjusted EPS reached $7.48, up 7%. At the same time, the company emphasizes that both figures included expenses for acquired research and development, acquired IPR&D, of $4.57 per share versus $0.71 a year earlier. These costs are related to portfolio development and materially affect comparability of results.
Lilly raised the midpoint of its 2026 revenue forecast by $5.5 billion to the $91–92 billion range. The updated adjusted EPS range is $35–36. According to the company's explanation, improvement in the underlying profit forecast was more than offset by acquired IPR&D expenses in the third quarter. Therefore, the revenue increase should not be automatically turned into a similar increase in forecasted EPS. Acquiring a research asset and current profit from the commercial portfolio have different time horizons.
For assessing fundamental value, it is useful to separately consider operating profit from existing drugs, capital expenditures for expanding production and the value of the research pipeline. Not every clinical project reaches registration, and successful registration does not guarantee profitability. Purchasing promising developments can create long-term value but is accompanied by the risk of write-offs and delays. A single P/E ratio is insufficient to correctly describe such a business structure.
Additional complexity arises from one-time receipts and revisions of discount estimates. Extrapolating the entire third quarter without normalization can overstate the sustainable profit base. A correct forecast must take into account net price dynamics, geographic mix, new products, seasonality and repeatability of individual contractual receipts. This is especially important when shares trade at a premium for sustained high growth.
Market reaction: strong company and expensive expectations
According to historical data from Lilly Investor Relations, the share closed on October 28 at $1,288.30, on October 29 at $1,373.70 and on October 30 at $1,417.54. These are confirmed closing prices for the indicated days, not the current quote at the time of reading the article. The movement coincided with the publication of clinical and financial news, but it cannot be fully attributed to one event without assessing the overall market and changes in positioning of participants.
The rise in the quote after the report is not a promise of further growth. The higher the premium for future earnings, the greater the sensitivity to an unexpected slowdown in volumes, margin deterioration or delay in registering a new drug. The company can continue to increase absolute profit while its shares decline if investors revise future growth rates. Therefore, business analysis and analysis of market valuation attractiveness must be separated.
For the entire sector the news has several implications. Competitors are accelerating research and negotiations with payers. Suppliers of manufacturing equipment receive potential demand for capacity expansion. Insurers can use the emergence of alternative drugs to improve purchasing terms. Biotechnology companies with promising molecules can attract capital, although the probability of clinical failures remains high. Gains from category expansion are distributed unevenly.
Scenarios for a one-year horizon
Base scenario, one–two quarters. Mounjaro and Zepbound continue to grow thanks to availability and geographic expansion, while realized prices remain under pressure. Gross margin is maintained by scale and product mix. Confirmation: volume growth, sustainability of profitability and fulfillment of the annual revenue range of $91–92 billion. Cancellation: accelerated decline in net price without cost compensation or deterioration in drug availability.
Positive scenario, six–twelve months. Manufacturing capacity expands without serious delays, insurance coverage becomes broader, and retatrutide receives additional convincing data and advances along the regulatory path. Then the market may raise its assessment of the duration of growth. Cancellation criteria: new serious safety signals, registration delays, underutilization of capacity or cannibalization of previous products without growth in aggregate profit.
Stress scenario, three–twelve months. Payers intensify price pressure, competitors close the clinical gap, and manufacturing and research expenses grow faster than cash flows. Even with high absolute revenue, margin expectations and stock valuation may decline. The scenario will be refuted by sustained gross and operating profitability, expanded access and successful execution of manufacturing plans.
These scenarios do not set guaranteed returns for LLY or competitors' shares. Calculating target prices would require verified market quotes, consistent cash flow forecasts and a separate assessment of the probability of registration of new drugs. It is especially dangerous to treat an experimental molecule as an already approved and fully monetized product. Clinical result, regulatory approval and commercial success remain three different events.
What the next quarter will test
The investor needs to monitor volumes, net price, gross margin, drug availability, insurance coverage and cash expenditures on production expansion simultaneously. For retatrutide, full scientific data, further safety results and regulatory decisions are required. For competitors, comparable studies should be compared, not metrics from different populations and therapy regimens.
Lilly demonstrates a rare combination: volumes are growing significantly faster than revenue, while gross margin is still improving. This is a strong position, but it must be confirmed in every new report. The wider the obesity treatment market, the more its economics depend on payers, mass production and long-term clinical value. The main intrigue is no longer the industry's ability to sell drugs worth tens of billions of dollars. It is what portion of those billions will become sustainable profit after expanded access and intensified competition.
Sources
Eli Lilly, October 29, 2026: third-quarter financial results, revenue, prices, volumes and forecast.
SEC, October 29, 2026: Lilly financial release and EPS notes.
Eli Lilly, October 28, 2026: TRANSCEND-T2D-2, methodology, efficacy and tolerability.
Eli Lilly Investor Relations: historical closing prices October 28–30, 2026.
Article prepared by the analytical department of TradePass